Literature DB >> 15682426

X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis.

Hirokazu Kanegane1, Yoshikiyo Ito, Koichi Ohshima, Takeshi Shichijo, Kunio Tomimasu, Keiko Nomura, Takeshi Futatani, Ryo Sumazaki, Toshio Miyawaki.   

Abstract

X-linked lymphoproliferative syndrome (XLP) is a rare, often fatal, primary immunodeficiency disease characterized by an abnormal response to Epstein-Barr virus (EBV) infection. The gene responsible for XLP has been identified as SH2D1A/DSHP/SLAM-associated protein (SAP). The major clinical manifestations include fulminant infectious mononucleosis, lymphoproliferative disorder, and dysgammaglobulinemia. Affected males uncommonly present with lymphocytic vasculitis in addition to aplastic anemia. In this study, we describe a Japanese XLP patient who presented with hypogammaglobulinemia following acute EBV-induced infectious mononucleosis in the infancy and later had systemic lymphocytic vasculitis and hemophagocytic lymphohistiocytosis in the adulthood, which resolved by steroid pulse therapy. The patient's SAP gene was found to harbor a missense mutation (His8Asp), presumably resulting in defective expression of SAP in T cells. Biopsy specimens of lung and skin disclosed that CD8+ T cells predominantly infiltrated vascular vessels. However, immunohistochemical examination showed that EBV-infected cells were not identifiable in the vessels. We propose that T-cell-mediated immune dysregulation in XLP can cause vasculitis by EBV infection-unrelated mechanism. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682426     DOI: 10.1002/ajh.20261

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.

Authors:  Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant.

Authors:  Paul E Gray; Tracey A O'Brien; Mayura Wagle; Stuart G Tangye; Umaimainthan Palendira; Tony Roscioli; Sharon Choo; Rosemary Sutton; John B Ziegler; Katie Frith
Journal:  J Clin Immunol       Date:  2015-10-03       Impact factor: 8.317

3.  Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency.

Authors:  Rebecca A Marsh; Jack J Bleesing; Alexandra H Filipovich
Journal:  J Immunol Methods       Date:  2010-09-09       Impact factor: 2.303

Review 4.  X-linked lymphoproliferative syndromes: brothers or distant cousins?

Authors:  Alexandra H Filipovich; Kejian Zhang; Andrew L Snow; Rebecca A Marsh
Journal:  Blood       Date:  2010-07-26       Impact factor: 22.113

5.  X-linked lymphoproliferative disease in an adult.

Authors:  Takumi Hoshino; Hirokazu Kanegane; Noriko Doki; Hiroyuki Irisawa; Tohru Sakura; Yoshihisa Nojima; Shuichi Miyawaki; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

6.  Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection.

Authors:  Kawsar R Talaat; Jennifer A Rothman; Jeffrey I Cohen; Mariarita Santi; John K Choi; Miguel Guzman; Robert Zimmerman; Sudha Nallasamy; Alexander Brucker; Martha Quezado; Stefania Pittaluga; Nicholas J Patronas; Amy D Klion; Kim E Nichols
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

Review 7.  Familial hemophagocytic lymphohistiocytosis: a model for understanding the human machinery of cellular cytotoxicity.

Authors:  Elena Sieni; Valentina Cetica; Elena Mastrodicasa; Daniela Pende; Lorenzo Moretta; Gillian Griffiths; Maurizio Aricò
Journal:  Cell Mol Life Sci       Date:  2011-10-12       Impact factor: 9.207

8.  Late-Onset Non-HLH Presentations of Growth Arrest, Inflammatory Arachnoiditis, and Severe Infectious Mononucleosis, in Siblings with Hypomorphic Defects in UNC13D.

Authors:  Paul Edgar Gray; Bella Shadur; Susan Russell; Richard Mitchell; Michael Buckley; Kerri Gallagher; Ian Andrews; Kevin Thia; Joseph A Trapani; Edwin Philip Kirk; Ilia Voskoboinik
Journal:  Front Immunol       Date:  2017-08-09       Impact factor: 7.561

Review 9.  X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective.

Authors:  Neelam Panchal; Claire Booth; Jennifer L Cannons; Pamela L Schwartzberg
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.